12K+ Oregon taxpayers impacted by Employment Department tax form error
PORTLAND, Ore. (KOIN) – If you're an unemployed Oregonian who has received a tax form from the Oregon Employment Department, you may want to double-check that it doesn't have an error.
The OED announced that at least 5% of the forms distributed in January for the 2024 tax year need to be updated — impacting at least 12,000 taxpayers in the state.
Amtrak Cascades now down to one train after Horizon fleet taken out of service
'We are very sorry for the inconvenience this caused some people,' OED director David Gerstenfeld said. 'The Employment Department is committed to providing people with accurate information as quickly as possible, which is why our employees are working hard to follow up with each impacted person with more specific information about their situation.'
The 1099-G tax form shows how much the OED paid out to those who used unemployment benefits in 2024. However, the use of a new system threw off how these totals are determined.
Before 2024, the OED relied upon a legacy system to pay Oregon's unemployment insurance program. The department then switched to its new system, , in March 2024.
Here's why Wednesday's weather in Portland failed to turn severe
Department officials said the form sent in January did not include both systems.
'This is the first time that 1099-G tax forms were created for the Unemployment Insurance program using Frances Online,' OED said. 'This is the only time that the new system will have to issue 1099-G forms covering payments made from both the new, and the legacy, systems.'
OED fixed the error on Monday and created new forms. Those who need a corrected form were contacted via automated message on Francis Online.
This follows months of complaints from those on unemployment who claim to have experienced since the website's launch.
It also follows Wednesday's announcement that — its highest since 2021 and .4% higher than the national average.
Stay with KOIN 6 News as we continue to follow this story.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics
ST. PAUL, Minn., June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. "The blood cancer burden on India's population is substantial, around 120,000 new cases of lymphoma, leukemia, and multiple myeloma are diagnosed each year. Unfortunately, almost 70,000 Indians will die every year from these afflictions, devastating the lives of their families and communities. To afford access to all Indian patients in need, and to capitalize on the immense commercial potential of our pipeline, we need to think prudently and practically about our manufacturing approach. In the short term, our manufacturing demands are almost 200 drug products per day, and this may increase as CAR-T cell therapies move closer to front line treatment. The only practical way for us to industrialize our production and produce a supply of drug product commensurate with total patient demand is to transition to G-Rex," said Dr. Lakshmikanth Gandikota, Head of R&D, MSAT Intellectual Property, and Translational Research, at Immuneel Therapeutics Limited. "We are extremely impressed by the speed, resourcefulness, creativity, discipline, and entrepreneurialism of the team at Immuneel and are happy to see that India, as a whole, is making significant strides toward CAR-T availability. It gives us a great sense of satisfaction to be in a position to help bring hope to cancer patients in India, one G-Rex at a time," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of Immuneel's G-Rex Grant, they will perform process development, qualification, and validation of a G-Rex based CAR-T cell therapy production approach to dramatically increase the throughput capacity of their state-of-the-art, 12,000 square foot GMP facility. Located in Bengaluru and opened in 2021, Immuneel's Integrated Cell Therapy Development and Manufacturing Facility was the first of its kind in India and is designed to bring breakthrough cell and gene therapies to millions of patients in India. Lastly, Immuneel's G-Rex Grant will support the requisite comparability studies necessary to support a post-CAR-T approval manufacturing change from their difficult to scale low throughput all-in-one manufacturing equipment to a much simpler high throughput G-Rex centric approach. The high popularity of ScaleReady's G-Rex Grant Program led ScaleReady to increase award funds from the original amount of $20M to a total of $30M directed towards saving recipients significant time and money by expediting the path to optimized cell and gene-modified cell therapy manufacturing. Two hundred grants have already been awarded with over 50 new applications in the queue. Each G-Rex Grant recipient can obtain up to $300,000 and gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. For more information about the G-Rex® Grant Program, please contact info@ About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Immuneel therapeutics Private LimitedImmuneel Therapeutics Private Limited is a cutting-edge biotechnology company based in Bangalore, India, at the forefront of advancing cell and gene therapies, as well as personalized immunotherapies, for cancer patients in India. As a research-driven and fully integrated organization, Immuneel is dedicated to making next-generation cancer treatments accessible and affordable, with a strong focus on innovation and clinical impact. The company's mission is to democratize advanced therapies by developing and commercializing breakthrough solutions tailored to the needs of Indian patients. As part of its growing portfolio, Immuneel has licensed and commercialized Qartemi® (varnimcabtagene autoleucel), a CD19 CAR-T cell therapy approved by India's Central Drugs Standard Control Organization (CDSCO) for the treatment of adult B-cell non-Hodgkin lymphoma a novel therapy for blood cancer, further demonstrating its commitment to transforming cancer care in India. Immuneel has a robust pipeline of CAR-T therapies for various indications in Oncology and AutoImmune diseases For more information, please visit: View original content to download multimedia: SOURCE Bio-Techne Corporation
Newsweek
a day ago
- Newsweek
IRS Issues Reminder of June Tax Deadline for Millions: What To Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Internal Revenue Service has reminded quarterly taxpayers that their second deadline of the year is approaching on Monday, June 16. Why It Matters Most employees pay their taxes on the annual deadline every April, but freelancers, small business owners and anyone else earning money that hasn't been subject to federal withholdings may have to submit quarterly payments four times a year. Filing and paying your taxes on time means you can avoid penalties. What To Know Federal taxpayers who earn income not subject to withholding—such as self-employment earnings, gig work, interest, dividends, capital gains, rental income, or 1099 payments—may need to make estimated tax payments during the year, the IRS says. Taxpayers—including sole proprietors, partners, and S corporation shareholders—who expect to owe at least $1,000 in taxes for the year are generally required to make estimated tax payments. Corporations must do the same if they anticipate a tax liability of $500 or more. Individual taxpayers earning money through gig work, freelance services, or the sale of goods may also need to pay estimated taxes, even if they receive a Form 1099-K. This includes those who also work regular jobs and have their income taxes removed via W-2 throughout the year by their employer. Internal Revenue Service sign at the IRS Building in Washington, DC, on March 14, 2018. Internal Revenue Service sign at the IRS Building in Washington, DC, on March 14, 2018. GETTY Form 1099-K reports of payments received for goods or services through payment cards (like credit, debit, or gift cards) and third-party platforms, such as payment apps or online marketplaces. To figure out your federal quarterly estimated tax payments, you'll need to estimate your adjusted gross income, taxable income, deductions, credits, and total taxes for the 2025 calendar year. If your income drops or increases throughout the year, you can adjust your quarterly payments as you go. Form 1040-ES includes an Estimated Tax Worksheet to guide you through the calculation. The June 16 deadline applies for income earned between April 1 and May 31st. How To Pay Quarterly Taxes Electronic payment is the fastest, safest, and most convenient way to pay, the IRS says. Taxpayers have several options, including: IRS Online Account or Direct Pay – Pay directly from a checking or savings account, or use a credit/debit card or digital wallet. Payment processors may charge a fee for card payments. – Pay directly from a checking or savings account, or use a credit/debit card or digital wallet. Payment processors may charge a fee for card payments. Electronic Federal Tax Payment System (EFTPS) – A secure federal payment system for individuals and businesses. – A secure federal payment system for individuals and businesses. Check or Money Order – Made payable to "United States Treasury" and submitted with Form 1040-ES. – Made payable to "United States Treasury" and submitted with Form 1040-ES. IRS2Go App – The official mobile app of the IRS for secure payments and resources. Further Payment Deadlines There are two further payment dates for 2025 taxes this year. The next is on September 15, 2025, for taxes payable for June 1 to August 31,and the final is on January 15, 2026 for income earned between September 1 to December 31.
Yahoo
a day ago
- Yahoo
P&G Appoints Craig Arnold to Board of Directors
CINCINNATI, June 09, 2025--(BUSINESS WIRE)--The Procter & Gamble Company (NYSE:PG) today announced the appointment of Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, to its Board of Directors, effective June 9, 2025. Mr. Arnold brings significant experience as a successful chief executive of a global enterprise serving businesses and customers in more than 175 countries. With a distinguished career at Eaton, a global leader in power infrastructure and technology, Arnold led the company through transformative changes from 2016 to May 2025. He was instrumental in incorporating renewable energy solutions and digital technologies into Eaton's portfolio, significant revenue and margin expansion and its contributions to environmental sustainability. Before his tenure as Chairman and CEO, Arnold served as President and Chief Operating Officer, overseeing strategic initiatives and operational excellence. His leadership from 2009 to 2015 as Vice Chairman and Chief Operating Officer of Eaton's Industrial Sector showcased his ability to drive results and impact at scale, boosting the company's performance and market presence. Mr. Arnold's career began at General Electric, where he held roles across the Appliances, Plastics and Lighting businesses, with international responsibilities spanning Asia, Europe, the Middle East and North America. His expertise in constructive disruption will provide valuable insights for P&G. Currently, Arnold serves as the lead independent board director for Medtronic, Inc. and is on the board of the United Way of Greater Cleveland and the Salvation Army of Greater Cleveland, actively participating in community initiatives that foster local engagement and industry collaboration. "Craig's depth of global experience, expertise managing diversified portfolios, and proven track record in innovation management and operational excellence will contribute valuable perspective to our efforts to better serve consumers and customers and grow markets," said Jon Moeller, P&G's Chairman of the Board, President, and Chief Executive Officer. About Procter & Gamble P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit for the latest news and information about P&G and its brands. For other P&G news, visit us at Category: PG-IR View source version on Contacts Media Contact:Henry Molski+1-513-505-3587 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
